NEW
YORK, Sept. 19, 2023 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Integra
LifeSciences Holdings Corporation.
Shareholders who purchased shares of IART during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/integra-loss-submission-form/?id=48631&from=4
CLASS PERIOD: March 11,
2019 to May 22, 2023
ALLEGATIONS: According to the complaint, defendants made
false statements and/or concealed that Integra had failed to take
sufficient measures to remediate the violations identified by the
FDA in the November 2, 2018 Notice of
Inspectional Observations on Form 483 (the "2018 Form 483"), the
March 6, 2019 FDA issued warning
letter (the "2019 Warning Letter"), and the November 12, 2021 FDA issued Form 483 (the "2021
Form 483"). As a result of those deficiencies, since March 2018, all products manufactured in the
Boston Facility had the potential for higher-than-permitted levels
of endotoxin and would need to be recalled. Moreover, the Company
was not making progress towards obtaining its premarket approval
("PMA") indication for SurgiMend, in part, because the
manufacturing site that would produce the PMA product, the Boston
Facility, was in continued violation of the FDA standards that
Integra failed to rectify years after the initial notice of the
violations and as a result the facility had to be shutdown to
correct those ongoing deficiencies.
DEADLINE: November 13, 2023
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/integra-loss-submission-form/?id=48631&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of IART during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is November 13, 2023. There is no
cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-integra-lifesciences-holdings-corporation-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-november-13-2023--nasdaq-iart-301931212.html
SOURCE The Gross Law Firm